Tattoos and Risk of Hematologic Cancer: A Population-Based Case–Control Study in Utah

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-10-23 DOI:10.1002/cam4.70260

Rachel D. McCarty, Britton Trabert, David Kriebel, Morgan M. Millar, Brenda M. Birmann, Laurie Grieshober, Mollie E. Barnard, Lindsay J. Collin, Katherine A. Lawson-Michod, Brody Gibson, Jenna Sawatzki, Marjorie Carter, Valerie Yoder, Jeffrey A. Gilreath, Paul J. Shami, Jennifer A. Doherty

{"title":"Tattoos and Risk of Hematologic Cancer: A Population-Based Case–Control Study in Utah","authors":"Rachel D. McCarty, Britton Trabert, David Kriebel, Morgan M. Millar, Brenda M. Birmann, Laurie Grieshober, Mollie E. Barnard, Lindsay J. Collin, Katherine A. Lawson-Michod, Brody Gibson, Jenna Sawatzki, Marjorie Carter, Valerie Yoder, Jeffrey A. Gilreath, Paul J. Shami, Jennifer A. Doherty","doi":"10.1002/cam4.70260","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Approximately one-third of US adults have a tattoo, and the prevalence is increasing. Tattooing can result in long-term exposure to carcinogens and inflammatory and immune responses.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We examined tattooing and risk of hematologic cancers in a population-based case–control study with 820 cases diagnosed 2019–2021 and 8200 frequency-matched controls, ages 18–79 years. We calculated odds ratios (OR) and 95% confidence intervals (CI) using multivariable-adjusted logistic regression models.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The prevalence of tattooing was 22% among Hodgkin lymphoma (HL) cases, 11% among non-Hodgkin lymphoma (NHL) cases, 16% among myeloid neoplasm cases, and 15% among controls. Though there were no clear patterns of associations between ever receiving a tattoo and risk of HL, NHL, or myeloid neoplasms overall, in analyses restricted to ages 20–60 years, ever receiving a tattoo (OR 2.06 [95% CI 1.01, 4.20]) and receiving a tattoo 10+ years prior (OR 2.64 [95% CI 1.23, 5.68]) were associated with an aggregated group of rarer mature B-cell NHLs. We also observed elevated risks for a 10+ year latency for myelodysplastic syndromes and chronic myeloid leukemia (OR 1.48 [95% CI 0.40, 5.41], and OR 1.24 [95% CI 0.45, 3.43], respectively).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Though estimates were imprecise, we found some suggestive evidence that tattooing may be associated with an increased risk of certain hematologic cancer subtypes. With an estimated 46% prevalence of tattooing in US individuals ages 30–49, additional studies are needed to understand the degree to which these exposures may be associated with hematologic cancer risk.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 20","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70260","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Approximately one-third of US adults have a tattoo, and the prevalence is increasing. Tattooing can result in long-term exposure to carcinogens and inflammatory and immune responses.

Methods

We examined tattooing and risk of hematologic cancers in a population-based case–control study with 820 cases diagnosed 2019–2021 and 8200 frequency-matched controls, ages 18–79 years. We calculated odds ratios (OR) and 95% confidence intervals (CI) using multivariable-adjusted logistic regression models.

Results

The prevalence of tattooing was 22% among Hodgkin lymphoma (HL) cases, 11% among non-Hodgkin lymphoma (NHL) cases, 16% among myeloid neoplasm cases, and 15% among controls. Though there were no clear patterns of associations between ever receiving a tattoo and risk of HL, NHL, or myeloid neoplasms overall, in analyses restricted to ages 20–60 years, ever receiving a tattoo (OR 2.06 [95% CI 1.01, 4.20]) and receiving a tattoo 10+ years prior (OR 2.64 [95% CI 1.23, 5.68]) were associated with an aggregated group of rarer mature B-cell NHLs. We also observed elevated risks for a 10+ year latency for myelodysplastic syndromes and chronic myeloid leukemia (OR 1.48 [95% CI 0.40, 5.41], and OR 1.24 [95% CI 0.45, 3.43], respectively).

Conclusions

Though estimates were imprecise, we found some suggestive evidence that tattooing may be associated with an increased risk of certain hematologic cancer subtypes. With an estimated 46% prevalence of tattooing in US individuals ages 30–49, additional studies are needed to understand the degree to which these exposures may be associated with hematologic cancer risk.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纹身与罹患血癌的风险：犹他州一项基于人群的病例对照研究。

背景：大约三分之一的美国成年人有纹身，而且这种现象还在不断增加。纹身可能导致长期暴露于致癌物质以及炎症和免疫反应：我们在一项基于人群的病例对照研究中研究了纹身与罹患血液系统癌症的风险，研究对象包括 820 例 2019-2021 年确诊的病例和 8200 例频率匹配的对照，年龄在 18-79 岁之间。我们使用多变量调整逻辑回归模型计算了几率比（OR）和95%置信区间（CI）：结果：在霍奇金淋巴瘤（HL）病例中，纹身的流行率为 22%；在非霍奇金淋巴瘤（NHL）病例中，纹身的流行率为 11%；在骨髓肿瘤病例中，纹身的流行率为 16%；在对照组中，纹身的流行率为 15%。虽然总体而言，曾经接受过纹身与罹患 HL、NHL 或髓样肿瘤的风险之间没有明显的关联模式，但在仅限于 20-60 岁的分析中，曾经接受过纹身（OR 2.06 [95% CI 1.01, 4.20]）和 10 年以上前接受过纹身（OR 2.64 [95% CI 1.23, 5.68]）与一组较罕见的成熟 B 细胞 NHL 相关。我们还观察到骨髓增生异常综合征和慢性髓性白血病潜伏期超过 10 年的风险升高（OR 分别为 1.48 [95% CI 0.40, 5.41] 和 OR 1.24 [95% CI 0.45, 3.43]）：尽管估计值并不精确，但我们发现了一些提示性证据，表明纹身可能与某些血液肿瘤亚型的风险增加有关。据估计，在 30-49 岁的美国人中，纹身的流行率为 46%，因此需要进行更多的研究，以了解这些暴露与血液学癌症风险的相关程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.